Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 46487 

and organizations (e.g. cancer patients, 

their families, the general public, health 

providers, the media, voluntary groups, 

scientific and medical organizations), it 

is beneficial for NCI to pretest their 

communications strategies, concepts, 

and messages while they are under 

development. The primary purpose of 

this pretesting, or formative evaluation, 

is to ensure that the messages, 

communication materials, and 

information services created by NCI 

have the greatest capacity of being 

received, understood, and accepted by 

their target audiences. By utilizing 

appropriate qualitative and quantitative 

methodologies, NCI is able to (1) 

understand characteristics of the 

intended target audience—their 

attitudes, beliefs, and behaviors—and 

use this information in the development 

of effective communication tools and 

strategies; (2) produce or refine 

messages that have the greatest potential 

to influence target audience attitudes 

and behavior in a positive manner; and 

(3) expend limited program resource 

dollars wisely and effectively. 

Frequency of Response: On occasion. 

Affected Public: Individuals or 

households; Businesses or other for 

profit; Not-for-profit institutions; 

Federal Government; State, Local, or 

Tribal Government. Type of 

Respondents: Adult cancer patients; 

members of the public; health care 

professionals; organizational 

representatives. The annual reporting 

burden is as follows: Estimated Number 

of Respondents: 13,780; Estimated 

Number of Responses per Respondent: 

1; Average Burden Hours Per Response: 

.1458; and Estimated Total Annual 

Burden Hours Requested: 2,010. The 

annualized cost to respondents is 

estimated at: $34,155. There are no 

Capital Costs, Operating Costs, and/or 

Maintenance Costs to report. 

ESTIMATE HOURS OF BURDEN

Type of respondents No. of respondents 

Frequency of 

response 

Average time 

per response 

Annual hour 

burden 

Adults 18+ ........................................................................................................ 13,780 1 .1458 2009.12 

Total .......................................................................................................... 13,780 ........................ ........................ 2009.12 

Request For Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Nina Goodman, 

Senior Analyst, Operations Research 

Office, OESI, NCI, NIH, 6116 Executive 

Blvd., Suite 400, Rockville, MD 20892, 

call non-toll-free number 301–435–7789 

or e-mail your request, including your 

address to: goodmann@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: August 2, 2006. 

Rachelle Ragland-Greene, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. E6–13190 Filed 8–11–06; 8:45 am] 

BILLING CODE 4101–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Real-Time Correction of Magnetic Field 

Fluctuations in MIR 

Description of Technology: Available 

for licensing is a new MRI technique 

that will markedly improve the 

diagnostic potential of the rendered 

images. This is a method for applying 

real-time corrections to prevent image 

distortions caused by field variations 

that are due to the patient’s respiratory 

cycle or instrument instability. These 

field variations reduce the B0

homogeneity in a non-uniform and 

spatially-dependent manner. They may 

lead to a variety of image artifacts such 

as ghosting and blurring. This method 

provides a way of calculating the correct 

electrical currents that must be applied 

to a set of gradients and shims, smaller 

magnets that are used to make fine-tune 

adjustments to the magnetic field in a 

spatially-dependent manner. As the MRI 

subject breathes, changes in the B0 field 

occur. During a brief training session, 

the amplitude of these changes as a 

function of chest motion is recorded in 

a phase map. Similarly, changes in B0 as 

a function of chest motion is recorded 

in a phase map. Similarly, changes in B0

as a function of current intensity is 

available from calibration data 

containing B0 as a function of coil 

current. As the subject undergoes a 

scan, compensatory currents are applied 

to the x, y, or z axis of the gradients and 

the shims coils in order to correct for 

the effect of respiration on the B0

homogeneity. The shim values can be 

updated every 10 to 80 milliseconds 


jlentini on PROD1PC65 with NOTICES
46488 Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 

during an experiment. This method 

results in a substantial decrease in 

artifacts that can obscure the overall 

image quality. It can be used for 

virtually all types of scans and MRI 

instruments. 

Applications: (1) Real-time correction 

of magnetic fluctuations in MRI 

experiments; (2) Improved MRI image 

precision. 

Market: MRI manufacturers, hospitals, 

medical research centers, and 

universities. 

Development Status: The technology 

is ready to be used and requires no 

further testing or development. 

Inventors: Jozef H. Duyn (NINDS), 

Peter van Gelderen (NINDS), et al. 

Related Publication: P van Gelderen, 

JA de Zwart, P Starewicz, RS Hinks, JH 

Duyn. Real time shimming for 

compensation of respiration induced 

field changes. Proceedings ISMRM 

2006, page 752. 

Patent Status: U.S. Provisional 

Application No. 60/781,246 filed 10 Mar 

2006 (HHS Reference No. E–085–2006/ 

0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Chekesha 

Clingman, Ph.D.; 301/435–5018; 

clingmac@mail.nih.gov 

Collaborative Research Opportunity: 

The National Institute of Neurological 

Disorders and Stroke is seeking 

statements of capability or interest from 

parties interested in collaorative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact Martha Lubet at 301/435–3120 

or lubetm@mail.nih.gov for more 

information. 

Microdialysis Probe for 

Musculoskeletal Tissue Stimulation 

and Biochemical Analysis 

Description of Technology: Available 

for licensing and commercial 

development is a microdialysis probe 

made from a small-bore (32 gauge) 

needle containing both a fluid delivery 

and recovery tube within the bore. A 

molecular exchange membrane is 

positioned about 200 microns from the 

tip. Fluid flows across the membrane 

removing diffused molecules to a 

collection device. The rounded tip of 

the needle is designed to cause minimal 

tissue damage while allowing 

investigations to be performed on local 

tissue fluids. Additionally, this device 

allows simultaneous delivery of small 

concentrations of drug to the area 

immediately surrounding the device tip. 

The device is actively used to study the 

pathophysiology of myofascial trigger 

points (MTrPs), a very common physical 

finding and cause of musculoskeletal 

pain and disability. The device allows 

for safe in situ exploration of myofascial 

pain biochemistry with minimal system 

perturbation. 

Applications: (1) Muscular 

stimulation; (2) Musculoskeletal pain; 

(3) Myofascial Trigger Points. 

Market: (1) Drug Discovery; (2) Pain 

management. 

Inventors: Jay Shah (NIHCC), Terence 

Martyn Phillips (ORS), Jerome V. Danoff 

(NIHCC), Lynn Gerber (NIHCC). 

Patent Status: U.S. Provisional 

Application No. 60/795,176 filed 27 Apr 

2006 (HHS Reference No. E–024–2006/ 

0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301/435–5019; 

shmilovm@mail.nih.gov 

Novel Infrared (IR)-Transparent 

Hydrophilic Membrane That Can be 

Used for Filtration, Printing or 

Microarrays, and Cultivation of 

Bacteria and Other Microorganisms for 

Reagent-Free IR Spectroscopic 

Identification 

Description of Technology: Available 

for licensing and commercial 

development is a novel, disposable 

infrared (IR)-transparent, microporous, 

plasma treated polyethylene 

hydrophilic membrane, as well as 

methods for making and using this 

membrane to identify bacterial and 

other micoorganism impurities in food 

using IR spectroscopy. Further 

applications include: filtering dilute 

aqueous bacterial suspensions, and 

growing bacterial colonies when the PE 

membrane is placed over an agar 

medium and incubated. The patent also 

describes a novel high-throughout 

technique, as an alternative to manual 

filtration, where the PE membrane is 

used for microarray printing of intact 

microorganisms in pre-enriched 

medium on the treated PE substrate. 

Furthermore, the invention relates to a 

method of detecting mixtures of foodborne pathogens E. sakazakii and K. 

pneumonia, by using the treated PE 

membranes. Because this unique 

membrane is transparent to infrared 

light, isolated microcolonies of bacterial 

cells grown on this PE substrate can be 

fingerprinted directly by IR 

microspectroscopy, followed by 

multivariate analysis for the 

identification of the pathogens. The 

method can be applied to other cell 

types as well. 

This novel membrane and its 

applications offer an advantage over 

existing tests in that it can be used to 

rapidly identify presumptive pathogen 

colonies, and can be used in screening 

tests for a large number of pathogens, as 

well as various microorganisms and cell 

types. It can also be used to isolate 

microorganisms from aqueous 

suspensions as well as spores, including 

airborne ones. 

Inventors: Magdi M. Mossoba and 

Sufian Al-Khaldi (FDA). 

Patent Status: U.S. Patent Application 

No. 11/343,561 filed 30 Jan 2006, 

entitled ‘‘Hydrophilic IR transparent 

membrane, spectroscopic sample holder 

comprising same and methods of using 

same’’ (HHS Reference No. E–174–2005/ 

0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contract: Cristina 

Thalhammer-Reyero, Ph.D., M.B.A.; 

301/435–4507; thalhamc@mail.nih.gov. 

Porcine Rotavirus Reassortant 

Compositions 

Description of Technology: 

Rotaviruses are the predominant cause 

of severe diarrhea and dehydration in 

infants and young children and are 

associated with approximately 600,000 

deaths each year worldwide. Although 

death from rotavirus infection occurs 

more frequently in developing countries 

an estimated 55,000–70,000 

hospitalizations and 20 to 60 deaths 

occur yearly in the United States. Thus, 

accelerating the availability of a safe and 

effective rotavirus vaccine represents a 

global public health priority. 

Available for licensing and 

commercial development are newly 

developed human rotavirus-porcine 

rotavirus reassortant vaccine 

compositions and methodology for their 

use in humans. This technology 

provides immunogenic compositions of 

reassortant human-porcine rotaviruses 

with VP7 specificity of the most 

clinically prevalent serotypes of human 

rotavirus found in various regions of the 

world. These compositions, which need 

clinical evaluation, should be able to 

induce an immunogenic response 

specific to human rotavirus serotypes 

that is protective against symptoms of 

serious rotaviral disease, such as severe 

diarrhea and dehydration. Porcine 

rotaviruses are genetically more closely 

related to human rotavirus strains 

compared to rhesus and bovine 

rotaviruses. 

Applications: (1) Resistance to 

developing severe human rotaviral 

disease; (2) Safe and effective global 

infant vaccinations. 

Market: (1) Rotaviral infections result 

in approximately 600,000 deaths yearly; 

(2) Anti-rotavirus technology has a 

projected market of more than 1.0 

billion dollars by 2010. 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 46489 

Development Status: Preclinical data 

is available at this time. 

Inventors: Yasutaka Hoshino and 

Albert Z. Kapikian (NIAID). 

Related Publications: 

1. Y Hoshino, RW Jones, J Ross, AZ 

Kapikian. Porcine rotavirus strain 

Gottfried-based human rotavirus 

candidate vaccines: construction and 

characterization. Vaccine 2005 May 

31;23(29):3791–3799. 

2. M Gorziglia, K Nishikawa, Y 

Hoshino, K Taniguchi. Similarity of the 

outer capsid protein VP4 of the 

Gottfried strain of porcine rotavirus to 

that asymptomatic human rotavirus 

strains. J Virology, 1990 Jan;64(1):414–

418. 

Patent Status: U.S. Provisional 

Application No. 60/698,572 filed 11 Jul 

2005 (HHS Reference No. E–056–2005/ 

0–US–01) 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Chekesha 

Clingman, Ph.D.; 301/435–5018; 

clingmac@mail.nih.gov. 

Adoptive T-Cell Transfer After 

Lymphodepletion Promotes Tumor 

Regression 

Description of Technology: Available 

for licensing is a method of adoptive 

cell transfer (ACT) immunotherapy. 

Since its first description, ACT is now 

being developed for the supportive 

treatment of a variety of infectious 

diseases and cancer. 

Current ACT methods to treat cancer 

are based on the ex vivo selection of 

lymphocytes with high avidity for 

recognition of tumor antigens, and their 

activation and numerical expansion 

before re-infusion to the autologous 

tumor-bearing host. The current 

invention improves ACT by including a 

pre-treatment regimen to ensure 

permissive conditions in the host for in 

vivo proliferation of the transferred 

cells. Specifically, the immune system 

is suppressed by pre-treatment with 

lymphodepleting chemotherapy. Two 

separate clinical trials have 

demonstrated that using this approach, 

ACT can induce lasting tumor 

shrinkage. 

Lymphodepleting chemotherapy 

followed by ACT resulted in tumor 

shrinkage of at least 50 percent in 6 out 

of 13 treated patients suffering from 

refractory melanoma. Several patients 

remained cancer free for more than a 

year after treatment. The usefulness of 

combined ACT and lymphodepleting 

therapy for cancer treatment was 

confirmed when this study was 

extended to include 35 melanoma 

patients. Eighteen of the 35 patients 

(51%) responded to the treatment, 

including 3 patients who experienced 

ongoing complete disappearance of 

cancer and 15 patients had tumor 

shrinkage of at least 50 percent with a 

mean duration of almost a year after 

treatment. In a recent clinical trial that 

is not yet published, using a modified 

protocol to treat 23 patients, a similar 

response rate (56%) was seen. 

This approach to ACT offers a 

potentially significant improvement in 

the treatment of many types of cancer. 

In addition, this method might be 

applicable in treating other diseases 

such as AIDS, immunodeficiency, or 

other autoimmunity for which immune 

effector cells can impact the clinical 

outcome. 

Inventors: Mark E. Dudley, Steven A. 

Rosenberg, John R. Wunderlich (NC). 

Publications: 

1. Dudley ME, et al. ‘‘Adoptive cell 

transfer therapy following nonmyeloablative but lymphodepleting 

chemotherapy for the treatment of 

patients with refractory metastatic 

melanoma.’’ J Clin Oncol. 2005 Apr 

1;23(10):2346–2357. 

2. Dudley ME, et al. ‘‘Cancer 

regression and autoimmunity in patients 

after clonal repopulation with antitumor 

lymphocytes.’’ Science. 2002 Oct 

25;298(5594):850–854. 

Patent Status: U.S. Provisional 

Application No. 60/408,681 filed 06 Sep 

2002 (HHS Reference No. E–275–2002/ 

0–US–01); PCT Application No. PC/ 

US03/27873 filed 05 Sep 2003, which 

published as WO 2004/021995 on 18 

Mar 2004 (HHS Reference No. E–275–

2002/1–PCT–01); U.S. Patent 

Application No. 10/526,697 filed 05 

May 2005 (HHS Reference No. E–275–

2002/1–US–02). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Michelle A. 

Booden, Ph.D.; 301/451–7337; 

boodenm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NCI Surgery Branch is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize ACT therapy. Please 

contact Steven A. Rosenberg, M.D., 

Ph.D. at 301/496–4164 for more 

information. 

Dated: July 28, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6872 Filed 8–11–06 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Hollow Waveguide Laser Delivery 

System for Digital Particle Image 

Velocity 

Description of Technology 

Available for licensing and 

commercial development is an allhollow-waveguide laser delivery system 

used for effective digital particle image 

velocimetry (DPIV) illumination. The 

System incorporates two key optical 

hollow waveguide components: An 

uncoated funnel-shaped hollow glass 

taper for a direct laser-to-taper coupling 

and a flexible hollow core waveguide 

for precise high-peak-power laser 

delivery. The principle of operation of 

the uncoated hollow taper is based on 

grazing-incidence effect. The optical 

taper is used for direct lens-free 

launching of laser radiation including 

from powerful lasers into fibers and 

waveguides. Because of the mutual 

action of the direct parallel laser 

excitation, the mode coupling process 

and mode filtering effect, the hollow 

taper serves as a mode converter that 

transforms the highly multimode profile 

of the input laser emission into a highquality Gaussian-shaped profile at the 

taper output. Moreover, because of the 

lower power density of the output laser 

beam and its high causality profile, the 


jlentini on PROD1PC65 with NOTICES